863329-65-1 Usage
Description
(2'R)-2'-Deoxy-2'-fluoro-2'-Methyl-uridine 3',5'-dibenzoate is a nucleoside analog with a unique chemical structure, featuring a deoxy, fluoro, and methyl modification at the 2' position, and a dibenzoate group at the 3' and 5' positions. (2'R)-2'-Deoxy-2'-fluoro-2'-Methyl-uridine 3',5'-dibenzoate has potential applications in various fields, particularly in the pharmaceutical industry.
Uses
Used in Antiviral Applications:
(2'R)-2'-Deoxy-2'-fluoro-2'-Methyl-uridine 3',5'-dibenzoate is used as an antiviral agent for its ability to inhibit the replication of certain viruses, such as the hepatitis C virus (HCV). It functions as a deaminated metabolite of β-D-2''-Deoxy-2''-fluoro-2''-C-methylcytidine, which has demonstrated effectiveness in inhibiting HCV replication in vitro.
Used in Pharmaceutical Industry:
(2'R)-2'-Deoxy-2'-fluoro-2'-Methyl-uridine 3',5'-dibenzoate is used as a key intermediate in the synthesis of various nucleoside analogs and antiviral drugs. Its unique chemical structure allows for the development of new therapeutic agents with improved efficacy and reduced side effects.
Used in Research and Development:
(2'R)-2'-Deoxy-2'-fluoro-2'-Methyl-uridine 3',5'-dibenzoate is used as a research compound for studying the mechanisms of viral replication and the development of resistance to antiviral drugs. It can also be employed as a tool to investigate the structure-activity relationships of nucleoside analogs and their potential applications in medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 863329-65-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,3,3,2 and 9 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 863329-65:
(8*8)+(7*6)+(6*3)+(5*3)+(4*2)+(3*9)+(2*6)+(1*5)=191
191 % 10 = 1
So 863329-65-1 is a valid CAS Registry Number.
863329-65-1Relevant articles and documents
AN IMPROVED PROCESS FOR THE PREPARATION OF SOFOSBUVIR
-
Page/Page column 5; 8, (2018/02/20)
The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of Sofosbuvir. The present invention involves use of reagents that are less expensive, easier to handle and eco-friendly process.
Biphenyl nucleoside phosphoramidate application of compound
-
Paragraph 0033; 0034; 0035, (2018/07/07)
The invention belongs to the field of medicinal chemistry, provided the present invention of the formula 1 compound or its pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or crystallization in preparation for the treatment of flavivirus, especially hepatitis c virus infection after the drug resistance of the patient, and/or prevention of drug-resistant patient disease onset or recurrence of the application of the medicament. The invention of the formula 1 compound has good medicine chest activity of HCV.
Synthesis method of sofosbuvir
-
, (2017/07/19)
The invention provides a synthesis method of sofosbuvir. The synthesis method of the sofosbuvir comprises the following steps: performing mitsunobu reaction on ((2R,3R,4R)-3-benzoyloxy)-4-fluorine-5-hydroxyl-4-methyltetrahydrofuran-2-yl)methyl benzoate to produce sulfonate to obtain a compound 1; abutting the compound 1 and N-benzoylcytosine to produce a compound 2. The method adopts mitsunobu reaction to avoid production of an isomer, and the isomer is reduced to 5 percent or below; according to the method, sulfonate and N-benzoylcytosine are abutted, so the use ofa stannic chloride raw material is avoided; furthermore, the yield is high and few solid waste is generated during aftertreatment, so that the method is suitable for large-scale industrialized production.
